# Evaluation of the Change in PSMA Expression in Prostate Cancer in Response to Hormonal Therapy

> **NCT05919329** · PHASE4 · RECRUITING · sponsor: **OHSU Knight Cancer Institute** · enrollment: 80 (estimated)

## Conditions studied

- Castration Resistant Prostate Cancer
- Castration Sensitive Prostate Cancer
- Prostate Adenocarcinoma

## Interventions

- **DRUG:** Piflufolastat
- **PROCEDURE:** PSMA PET/CT Scan
- **PROCEDURE:** PSMA PET/MRI scan
- **PROCEDURE:** Biospecimen Collection
- **OTHER:** Electronic Health Record Review

## Key facts

- **NCT ID:** NCT05919329
- **Lead sponsor:** OHSU Knight Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-25
- **Primary completion:** 2028-09-01
- **Final completion:** 2030-09-01
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2025-10-24

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05919329

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05919329, "Evaluation of the Change in PSMA Expression in Prostate Cancer in Response to Hormonal Therapy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05919329. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*